In the present invention there is disclosed a process for preparing a lyophilized preparation containing pantoprazole wherein the preoparation process comprises freeze-drying of an aqueous solution of pantoprazole ethylenediamine tetraacetic acid and/or a suitable salt thereof and sodium hydroxide and/or sodium carbonate. The thus obtained preparations have advantageous properties when reconstituted for injection.

Taste masked dosage forms for oral administration of roflumilast are described.

The invention relates to the use of Roflumilast Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.

The invention relates to the combined administration of roflumilast and formoterol for the treatment of respiratory tract disorders.

Dosage forms for oral administration of the magnesium salt of pantoprazole are described.

A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight and N-(35-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.

603207 Disclosed is a pharmaceutical composition and a combination product comprising Roflumilast also known as 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4- (difluoromethoxy)benzamide

A method for the treatment of chronic obstructive pulmonary disease (COPD) including administering to a patient suffering from COPD a therapeutically effective amount of roflumilast having a purity of greater than or equal to 99% by weight and N-(35-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.